An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols.

Trial Profile

An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Tivantinib (Primary)
  • Indications Colorectal cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Renal cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors ArQule
  • Most Recent Events

    • 12 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 12 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 15 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top